Dihydromyricetin

DB15645InvestigationalSmall molecule

Dihydromyricetin is under investigation in clinical trial NCT03606694 (Effect of Dihydromirycetin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes Mellitus).

Mechanism: Pharmacologically active on Tyrosinase and Replicase polyprotein 1ab
Curator reviewed
Formula / weight: C₁₅H₁₂O₈ · 320.251 g/mol (avg)
Also known as: (+)-ampelopsin · (+)-dihydromyricetin · Ampelopsin · Ampeloptin · Telocapil

Resolves to

Compound

UNIIKD8QND6427CAS27200-12-0ChEMBLCHEMBL3348861ChEBI28429KEGGC02906

Clinical / RWD

RxNorm356879

Structure

InChIKeyKJXSIXMJHKAJOD-LSDHHAIUSA-NSMILESO[C@@H]1[C@H](OC2=C(C(O)=CC(O)=C2)C1=O)C1=CC(O)=C(O)C(O)=C1

Targets

P14679TYRP0DTD1rep

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dihydromyricetin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account